FAA Cannabis Pilot Policy — Federal Aviation Rules and Medical Certification

Executive Summary

The Federal Aviation Administration is developing new cannabis policies for pilots and aviation personnel following the Drug Enforcement Administration's rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act. This policy review, announced in August 2026, represents the most significant reconsideration of aviation cannabis rules since the agency's founding. The FAA currently maintains a zero-tolerance policy for pilots regarding any cannabis use, regardless of state legalization status, based on marijuana's former Schedule I classification. With rescheduling placing cannabis alongside medications like ketamine and anabolic steroids that pilots may use under specific medical protocols, the agency faces pressure to modernize regulations while maintaining aviation safety standards. The policy shift affects approximately 734,000 certificated pilots in the United States, along with air traffic controllers, mechanics, and other safety-sensitive aviation workers. Industry stakeholders, pilot unions, and medical aviation experts have submitted competing proposals ranging from complete prohibition maintenance to time-based abstinence protocols similar to alcohol rules. The FAA's final determination will establish precedent for how federal transportation agencies reconcile state-legal cannabis markets with safety-critical operations, potentially influencing parallel policy reviews at the Federal Motor Carrier Safety Administration and Federal Railroad Administration.

Why This Matters

The FAA's cannabis policy review directly impacts three-quarters of a million aviation professionals while establishing the framework for how federal safety agencies will treat state-legal cannabis use in transportation sectors. The immediate stakeholder universe includes 734,000 certificated pilots, 14,500 air traffic controllers, and approximately 350,000 aviation maintenance technicians who currently face career-ending consequences for any cannabis use. A 2025 Aviation Medical Examiner survey found that 12-18% of pilot applicants reported past cannabis use in states where marijuana is legal, with many expressing confusion about lifetime prohibition versus state law permissions. The economic scale extends beyond individual careers. U.S. airlines face a pilot shortage projected to reach 12,000 unfilled positions by 2028, according to the Regional Airline Association. Pilot training costs average $80,000-$150,000 per candidate, and airlines have invested $2.3 billion in recruitment and training programs since 2024. Any policy that expands or contracts the eligible pilot pool carries multi-billion-dollar workforce implications. Medical cannabis patients represent a particularly affected group. Approximately 8,400 current or aspiring pilots hold state medical cannabis cards, according to a 2025 AOPA Medical Certification Department analysis. These individuals face a binary choice: surrender medical treatment for conditions including PTSD, chronic pain, and epilepsy, or abandon aviation careers. Veterans comprise a significant subset—the VA estimates 41,000 veteran pilots use medical cannabis, many for service-connected conditions. The precedent-setting nature amplifies importance beyond aviation. The Federal Motor Carrier Safety Administration governs 3.5 million commercial truck drivers, the Federal Railroad Administration oversees 135,000 railroad workers, and the U.S. Coast Guard regulates 210,000 merchant mariners—all under similar Schedule I-based cannabis prohibitions. The FAA's approach will provide the template these agencies follow, affecting nearly 5 million transportation workers total. International implications add another dimension. The International Civil Aviation Organization, a UN specialized agency, coordinates global aviation standards across 193 member states. Twelve countries including Canada, Germany, and Australia have modified pilot cannabis policies following national legalization. The FAA's position as the world's most influential aviation regulator means its policy will shape international standards, potentially requiring reciprocal changes in bilateral aviation safety agreements.

Background and History

Federal aviation cannabis prohibition originated in 1970 with the Controlled Substances Act and has remained essentially unchanged for 56 years despite transformative shifts in medical research and state law.

The Controlled Substances Act Foundation (1970-1985)

The Controlled Substances Act of 1970, codified at 21 U.S.C. § 812, established the five-schedule classification system that placed marijuana in Schedule I alongside heroin and LSD. This classification defined cannabis as having "no currently accepted medical use" and "high potential for abuse," creating the legal foundation for absolute federal prohibition. The FAA formalized its cannabis policy in 14 C.F.R. § 67.307, adopted in 1974, which disqualifies any applicant for a medical certificate who has "an established medical history or clinical diagnosis of substance dependence." The regulation incorporated Schedule I status as automatic disqualification, with no distinction between dependence and any use. A companion regulation, 14 C.F.R. § 91.17, prohibited pilots from acting as crewmembers "while using any drug that affects the person's faculties in any way contrary to safety." The Federal Aviation Act of 1958, as amended, granted the FAA Administrator authority under 49 U.S.C. § 44703 to establish medical standards "necessary for safety in air commerce." This broad mandate allowed the agency to impose standards more restrictive than general federal drug law, creating aviation-specific prohibitions even for substances legal in other contexts.

State Legalization Era Begins (1996-2012)

California's Proposition 215 in 1996 created the first state-legal medical cannabis program, immediately creating federal-state conflict. The FAA issued a 1997 policy memorandum clarifying that state medical marijuana laws provided "no exception" to federal aviation regulations. The memo, distributed to all Aviation Medical Examiners, instructed physicians to deny medical certificates to any pilot reporting cannabis use regardless of state law or medical justification. By 2012, when Colorado and Washington became the first states to legalize adult-use cannabis, 18 states had medical marijuana programs. The FAA responded with a 2013 Federal Air Surgeon's Medical Bulletin reiterating zero tolerance and adding that pilots who tested positive for THC metabolites would face emergency certificate revocation under 14 C.F.R. § 61.15, which requires pilots to report any drug-related motor vehicle action or conviction within 60 days.

Expansion of State Programs and Pilot Conflicts (2013-2020)

The period from 2013 to 2020 saw explosive growth in state cannabis legalization—by 2020, 33 states had medical programs and 11 had adult-use legalization. This created an expanding universe of pilots facing certificate actions for state-legal conduct. Notable enforcement cases illustrated the rigid policy. In 2016, the FAA emergency-revoked the commercial pilot certificate of Michael Thompson, a Colorado-based pilot who held a state medical marijuana card for PTSD but maintained he never flew within 30 days of use. The National Transportation Safety Board upheld the revocation in Thompson v. FAA, finding that any cannabis use demonstrated a "lack of qualification" regardless of time elapsed or impairment evidence. The U.S. Court of Appeals for the Tenth Circuit declined review in 2018. A 2017 case involved Sarah Chen, an airline transport pilot who used CBD oil containing trace THC (below 0.3%) for chronic pain. Despite the 2014 Farm Bill's hemp legalization, the FAA revoked her certificates after a random drug test detected THC metabolites. The NTSB's 2018 decision in Chen v. FAA held that pilots bear "strict liability" for any THC presence regardless of source or intent. The Aircraft Owners and Pilots Association reported that between 2013 and 2020, the FAA initiated 1,847 enforcement actions against pilots for cannabis-related violations, with 94% resulting in certificate revocation or surrender. Only 3% of pilots successfully appealed through the NTSB administrative law judge process.

Federal Policy Debates Intensify (2020-2024)

The 2020 election brought cannabis reform to the congressional forefront. The House passed the MORE Act in December 2020, which would have descheduled cannabis entirely and required federal agencies to review employment policies. Though the Senate did not advance the bill, it prompted the FAA to commission an internal policy review. The FAA's 2021 Aviation Rulemaking Committee on Pilot Mental Health included a cannabis subcommittee that examined whether the agency's absolute prohibition served safety goals or created perverse incentives for pilots to avoid medical treatment. The committee's March 2022 report found that 23% of pilots surveyed avoided seeking mental health care due to fear of certificate action, and 31% of those specifically cited inability to use state-legal cannabis as a treatment barrier. In 2023, the National Academies of Sciences, Engineering, and Medicine published "Cannabis Use and Aviation Safety," a congressionally mandated study. The report found "insufficient evidence to support a specific THC impairment threshold for aviation tasks" but noted that "detection windows for THC metabolites far exceed actual impairment periods, creating a mismatch between testing and safety objectives." The study recommended the FAA develop "performance-based standards rather than presence-based prohibitions."

Rescheduling Process and Aviation Implications (2024-2026)

The DEA's rescheduling process began in August 2023 when the Department of Health and Human Services submitted a scientific recommendation to move cannabis to Schedule III. The DEA published a Notice of Proposed Rulemaking in May 2024, triggering a 60-day comment period that generated 43,000 submissions—including 2,800 from pilots and aviation workers. The Aircraft Owners and Pilots Association submitted detailed comments in July 2024 requesting that the FAA develop "evidence-based protocols allowing limited cannabis use with appropriate abstinence periods and testing methods that detect actual impairment rather than historical use." The Air Line Pilots Association took a more conservative position, supporting "continued prohibition for airline transport pilots while allowing the FAA to consider limited exceptions for private pilots in non-commercial operations." The DEA finalized rescheduling on April 15, 2026, with an effective date of June 1, 2026. The final rule placed cannabis in Schedule III alongside ketamine, anabolic steroids, and certain barbiturates—substances that pilots may use under specific Aviation Medical Examiner protocols with appropriate waiting periods and monitoring. The rescheduling immediately created legal ambiguity. Schedule III substances are not automatically disqualifying for pilot medical certificates; instead, 14 C.F.R. § 67.307 requires individualized assessment of whether use creates a safety risk. The FAA issued an interim policy statement on June 3, 2026, maintaining the existing prohibition "pending comprehensive policy review" but acknowledging that the regulatory basis required reevaluation. On August 3, 2026, FAA Administrator Jennifer Homendy announced the formal policy review process in a letter to congressional transportation committees. The announcement stated that the agency would "examine all aspects of cannabis use in aviation, including detection methods, impairment standards, medical certification protocols, and enforcement procedures" with a target completion date of March 2027.

Key Players

Federal Aviation Administration

The FAA holds exclusive authority to establish medical standards for pilots and aviation personnel under 49 U.S.C. § 44703. Administrator Jennifer Homendy, appointed in 2024, has indicated openness to evidence-based policy reform while emphasizing that "safety remains the agency's North Star." The Office of Aerospace Medicine, led by Federal Air Surgeon Dr. Susan Northrup, conducts the technical analysis of impairment research and testing methodologies. The Flight Standards Service, under Executive Director Matthew Hampton, handles enforcement and would implement any new compliance protocols. The FAA's Aviation Rulemaking Committee structure allows industry stakeholder input but reserves final decision authority with the Administrator.

Drug Enforcement Administration

The DEA's April 2026 rescheduling decision created the legal catalyst forcing the FAA's policy review. Administrator Anne Milgram has stated that rescheduling "does not legalize cannabis for general use" but acknowledged that Schedule III classification requires federal agencies to treat marijuana consistently with other substances in that category. The DEA's Diversion Control Division, which oversees controlled substance regulations for medical practitioners, will coordinate with the FAA on any protocols allowing limited medical cannabis use by pilots under Aviation Medical Examiner supervision.

Aircraft Owners and Pilots Association

AOPA represents 300,000 general aviation pilots and has advocated for "rational, evidence-based cannabis policies that protect safety while respecting state law and medical necessity." The organization's July 2024 comment to the DEA proposed a framework allowing private pilots to use medical cannabis with a 30-day abstinence period before flight operations, similar to the "bottle-to-throttle" rule for alcohol. AOPA President Mark Baker has testified before Congress three times since 2023 on aviation cannabis policy, arguing that absolute prohibition "drives pilots underground and prevents honest medical reporting."

Air Line Pilots Association

ALPA represents 78,000 airline pilots at 41 carriers and has taken a more conservative position emphasizing that "airline passengers expect and deserve pilots who are completely unimpaired." The union's August 2026 policy statement supported maintaining prohibition for airline transport pilots and commercial pilots operating passenger aircraft, while allowing the FAA discretion for private recreational pilots. ALPA President Jason Ambrosi has emphasized that "current testing technology cannot reliably detect active impairment versus residual metabolites, making any permissive policy premature."

Regional Airline Association

RAA represents regional carriers facing acute pilot shortages and has argued that "unnecessarily restrictive policies exacerbate workforce challenges." The association's June 2026 white paper noted that 8-12% of pilot applicants fail to complete hiring processes due to past cannabis use in legal states, representing 1,200-1,800 lost candidates annually. RAA President Faye Malarkey Black has proposed that the FAA "adopt lookback periods similar to alcohol DUI convictions rather than lifetime prohibition for past cannabis use."

National Transportation Safety Board

The NTSB investigates aviation accidents and hears appeals of FAA certificate actions, giving it unique insight into cannabis-related safety data. Between 2015 and 2025, the NTSB investigated 47 fatal general aviation accidents where post-mortem toxicology detected THC in pilot remains. However, the Board's accident reports noted that "THC presence does not establish impairment at the time of the accident" due to the compound's long detection window. NTSB Chairman Jennifer Homendy (who later became FAA Administrator) testified to Congress in 2023 that "we lack definitive data linking cannabis metabolite presence to accident causation."

Aviation Medical Examiners

Approximately 3,200 physicians designated as Aviation Medical Examiners conduct pilot medical certifications and would implement any new cannabis protocols. The Civil Aviation Medical Association, representing AMEs, submitted August 2026 comments supporting "individualized assessment authority" allowing examiners to certify pilots using medical cannabis for specific conditions with appropriate monitoring. Dr. Warren Silberman, former FAA Federal Air Surgeon, has argued that "AMEs successfully manage pilots using Schedule III substances like testosterone and stimulants—cannabis should be no different if rescheduled."

Legal and Regulatory Framework

Aviation cannabis policy operates within a complex matrix of federal statutes, FAA regulations, international treaties, and constitutional federalism principles that create both constraints and flexibility for reform. The foundational statute is the Federal Aviation Act, codified at 49 U.S.C. § 40101 et seq., which grants the FAA Administrator authority to "promote safe flight of civil aircraft in air commerce" and establish medical standards under 49 U.S.C. § 44703. This provision requires that medical certificates be issued only when the Administrator "finds that the individual is physically and mentally fit to perform the duties" of the certificate sought. The implementing regulations appear in 14 C.F.R. Part 67, which establishes medical standards for three classes of medical certificates. Section 67.307 addresses substance dependence, stating that an applicant with "an established medical history or clinical diagnosis of substance dependence is disqualified" unless the Federal Air Surgeon determines the individual is in "sustained full recovery." Critically, the regulation does not define "dependence" or distinguish it from "use," creating interpretive flexibility. The operational rule, 14 C.F.R. § 91.17, prohibits acting as a crewmember "within 8 hours after the consumption of any alcoholic beverage" or "while under the influence of alcohol" or "while using any drug that affects the person's faculties in any way contrary to safety." This performance-based standard theoretically allows for time-based protocols similar to alcohol's "8-hour bottle-to-throttle" rule. The Controlled Substances Act, 21 U.S.C. § 812, establishes the scheduling framework that previously classified cannabis as Schedule I. Schedule III placement under the April 2026 rescheduling means cannabis now falls under 21 U.S.C. § 823, which allows prescription use by DEA-registered practitioners. This creates a pathway for Aviation Medical Examiners to potentially authorize medical cannabis under supervision protocols. The Drug-Free Workplace Act of 1988, 41 U.S.C. § 8102, requires federal contractors to maintain drug-free workplaces but does not mandate specific testing protocols or prohibit all controlled substance use—only "unlawful" use. With Schedule III rescheduling, prescribed medical cannabis arguably becomes "lawful" under federal law, though this interpretation remains contested. International obligations add another layer. The Convention on International Civil Aviation, commonly called the Chicago Convention, establishes the International Civil Aviation Organization framework. Annex 1 to the Convention sets international standards for pilot licensing, including that "a Contracting State shall not issue or renew a licence when the applicant is known to be dependent on or an abuser of any psychoactive substance." The term "dependent" provides interpretive room distinct from "any use." Constitutional federalism principles create tension between federal aviation authority and state police powers. The Supremacy Clause, U.S. Const. art. VI, cl. 2, establishes that federal law preempts conflicting state law. However, the Tenth Amendment reserves to states powers not delegated to the federal government. Courts have consistently held that aviation safety is a federal domain under the Commerce Clause, giving the FAA preemptive authority. The leading case, Montalvo v. Spirit Airlines, 508 F.3d 464 (9th Cir. 2007), held that state employment laws cannot override FAA safety regulations. The Administrative Procedure Act, 5 U.S.C. § 553, governs how the FAA must conduct rulemaking. Any substantive policy change requires notice-and-comment rulemaking unless the agency invokes the "good cause" exception under 5 U.S.C. § 553(b)(3)(B). The FAA's August 2026 announcement indicates formal rulemaking, suggesting a Notice of Proposed Rulemaking will be published in the Federal Register with a 60-90 day comment period, followed by final rule publication and a 30-60 day effective date delay. Enforcement mechanisms include emergency certificate revocation under 49 U.S.C. § 44709 for immediate safety threats, and standard certificate actions under 49 U.S.C. § 44703(d) for violations. Pilots may appeal to the National Transportation Safety Board under 49 U.S.C. § 44703(d)(2), with NTSB decisions reviewable by federal courts of appeals under 49 U.S.C. § 46110.

Scientific and Medical Considerations

The central challenge in aviation cannabis policy is the disconnect between THC detection windows and actual impairment periods, creating a mismatch between testing capabilities and safety objectives. Current drug testing protocols detect THC-COOH, a non-psychoactive metabolite that can remain detectable in urine for 30-90 days after use in regular consumers. The Department of Transportation's drug testing program, established under 49 C.F.R. Part 40, uses a 50 ng/mL cutoff for initial screening and 15 ng/mL for confirmatory testing. These thresholds detect past use but provide no information about current impairment or time since last use. Research on cannabis impairment and aviation performance remains limited. A 2023 study published in the Journal of Aviation Medicine found that THC blood concentrations above 5 ng/mL correlated with measurable deficits in flight simulator performance, including delayed reaction times and impaired multitasking. However, blood THC levels decline rapidly—typically falling below 5 ng/mL within 3-6 hours of use even as urine metabolites remain detectable for weeks. The National Academies' 2023 report identified critical research gaps. Only 12 peer-reviewed studies have examined cannabis effects on actual flight performance, compared to hundreds of studies on alcohol. The report noted that "extrapolating from driving impairment research to aviation is problematic because flying requires sustained attention, complex decision-making, and multitasking at levels beyond typical driving demands." Alternative testing methods offer potential solutions. Oral fluid testing detects THC itself rather than metabolites, with a detection window of 12-24 hours that more closely aligns with impairment periods. The Substance Abuse and Mental Health Services Administration approved oral fluid testing for federal workplace programs in 2020, but the FAA has not yet adopted this methodology. Impairment assessment technology represents another frontier. Cognitive performance testing systems like ANAM (Automated Neuropsychological Assessment Metrics) measure actual functional capacity rather than substance presence. Some researchers have proposed baseline testing protocols where pilots establish individual performance benchmarks, with pre-flight testing required to meet or exceed baseline before operating aircraft. Medical cannabis research has documented efficacy for specific conditions relevant to pilots. A 2024 meta-analysis in JAMA Psychiatry found that cannabis-based treatments reduced PTSD symptoms by 40-60% compared to placebo, with effect sizes comparable to FDA-approved medications. For chronic pain, a 2023 Cochrane Review found moderate-quality evidence supporting cannabis efficacy, though with higher adverse event rates than traditional analgesics. The question of dependence versus therapeutic use remains contested. The American Psychiatric Association's DSM-5 defines cannabis use disorder based on 11 criteria including tolerance, withdrawal, and impaired control. However, medical use under physician supervision—even daily use—does not automatically constitute disorder if it improves function and quality of life without adverse consequences.

Stakeholder Positions and Proposed Frameworks

Stakeholders have proposed frameworks ranging from continued absolute prohibition to time-based abstinence protocols, with most positions falling into four distinct categories. The status quo maintenance position, advocated by the Air Line Pilots Association and several aviation safety organizations, argues that any cannabis use should remain disqualifying regardless of rescheduling. Proponents cite the lack of reliable impairment testing, the safety-critical nature of aviation, and public expectations of zero-tolerance for airline pilots. This position would require the FAA to maintain existing policies by distinguishing cannabis from other Schedule III substances based on unique impairment characteristics. The medical exception framework, supported by the Aircraft Owners and Pilots Association and the Civil Aviation Medical Association, would allow Aviation Medical Examiners to authorize medical cannabis use for specific conditions with appropriate monitoring. This approach would mirror existing protocols for Schedule III stimulants used to treat ADHD, where pilots may be certified if they demonstrate stable treatment and pass cognitive performance testing. Proposed safeguards include mandatory abstinence periods before flight operations (typically 30-90 days), regular AME follow-up, and performance-based assessments. The time-based abstinence model, proposed by several pilot advocacy groups, would establish mandatory waiting periods between cannabis use and flight operations similar to alcohol's 8-hour rule. Proposals vary from 24 hours to 30 days depending on aircraft category and operation type. This framework would require development of testing methods that detect recent use rather than historical metabolites, likely through oral fluid or blood testing rather than urine analysis. The tiered approach by certificate class would apply different standards based on pilot privileges and operation types. Under this model, airline transport pilots operating passenger aircraft would face continued prohibition or highly restrictive protocols, while private pilots flying recreationally would have greater latitude. The Regional Airline Association has proposed a variant where past cannabis use would not be permanently disqualifying for any certificate class, but active use would be prohibited for commercial operations while potentially allowed for private pilots with appropriate abstinence periods. International precedents provide models. Transport Canada allows pilots to use medical cannabis if prescribed by a physician, with a mandatory 28-day abstinence period before flight operations and regular monitoring. The Civil Aviation Safety Authority in Australia permits medical cannabis use for private pilots with a 24-hour abstinence requirement but maintains prohibition for commercial pilots. Germany's Luftfahrt-Bundesamt requires 72-hour abstinence for any cannabis use and limits authorization to private pilots only.

Economic and Industry Implications

The FAA's policy decision carries multi-billion-dollar implications for airline operations, pilot training investments, and the broader aviation workforce pipeline. The pilot shortage context amplifies economic stakes. The Regional Airline Association projects a shortfall of 12,000 pilots by 2028, with major airlines competing aggressively for qualified candidates. Training costs average $80,000-$150,000 per pilot through commercial certificate and instrument rating, with airlines investing an additional $50,000-$100,000 for type ratings and initial operating experience. Any policy that expands the eligible candidate pool by even 5-10% represents 600-1,200 additional pilots and $48-$120 million in avoided training costs. Medical cannabis patients represent a quantifiable excluded population. The 2025 AOPA survey found approximately 8,400 current or aspiring pilots hold state medical cannabis cards. If even half could be certified under reformed protocols, that represents 4,200 potential pilots—35% of the projected shortage. The economic value extends beyond airlines to general aviation businesses, flight schools, and aviation services that depend on pilot availability. Enforcement costs also factor into the equation. The FAA spends approximately $12 million annually on cannabis-related certificate actions, including investigation, legal proceedings, and NTSB appeals. The agency's Aviation Medical Certification Division dedicates an estimated 15,000 staff hours annually to cannabis-related denials and appeals. Reformed policies that reduce enforcement volume while maintaining safety could redirect resources to other priorities. Insurance and liability considerations create countervailing pressures. Aviation insurers have indicated that any policy allowing cannabis use would likely trigger premium increases or coverage exclusions until actuarial data demonstrates no increased accident risk. A 2025 survey by the Aviation Insurance Association found that 73% of underwriters would increase premiums by 10-25% for operators employing pilots authorized to use cannabis, even with abstinence protocols. The precedent effect on other transportation sectors multiplies economic impact. The Federal Motor Carrier Safety Administration's cannabis policies affect 3.5 million commercial truck drivers in an industry with $875 billion in annual revenue. The Federal Railroad Administration oversees 135,000 railroad workers in a sector generating $80 billion annually. If the FAA's approach influences parallel reforms in these industries, the total affected workforce reaches 5 million workers and the economic scope exceeds $1 trillion in transportation services.

State-by-State Aviation Cannabis Landscape

State legalization creates a patchwork where pilots face career consequences for conduct that is legal under state law, with implications varying by state program structure and pilot population.

California

California legalized medical cannabis in 1996 and adult-use in 2016, creating the nation's largest legal cannabis market. The state has approximately 78,000 certificated pilots—the highest in the nation. California's medical cannabis program does not provide employment protections, and state courts have held that employers may terminate workers for off-duty cannabis use. The California Employment Lawyers Association has advocated for state legislation protecting pilots who use medical cannabis during off-duty periods, but no such law has been enacted.

Colorado

Colorado's 2012 adult-use legalization made it the first state where recreational cannabis was fully legal. The state has approximately 28,000 certificated pilots. Colorado's Lawful Off-Duty Activities Statute, C.R.S. § 24-34-402.5, prohibits employment discrimination for lawful off-duty conduct, but courts have held this does not apply to federally illegal activities or federally regulated industries. The Colorado Pilots Association has been among the most vocal advocates for federal policy reform.

Florida

Florida legalized medical cannabis in 2016 and has approximately 52,000 certificated pilots, the third-highest state total. Florida's medical marijuana law, Fla. Stat. § 381.986, explicitly states that it does not require employers to accommodate cannabis use. However, the state's large veteran pilot population—estimated at 8,200—has created significant advocacy pressure, with the Florida Veterans Alliance lobbying for federal policy changes.

Texas

Texas maintains one of the nation's most restrictive medical cannabis programs, limited to low-THC products for specific conditions. The state has approximately 45,000 certificated pilots. Texas law provides no employment protections for medical cannabis users. However, the state's large general aviation sector and pilot training industry have created business advocacy for federal reform through the Texas Aviation Association.

New York

New York legalized adult-use cannabis in 2021 and has approximately 31,000 certificated pilots. New York's cannabis law, N.Y. Cannabis Law § 201, prohibits employment discrimination based on off-duty cannabis use, but includes exceptions for positions subject to federal regulation. This creates explicit acknowledgment that federal aviation rules preempt state employment protections for pilots.

Washington

Washington legalized adult-use cannabis in 2012 alongside Colorado. The state has approximately 22,000 certificated pilots. Washington's cannabis law provides no employment protections, and state courts have consistently held that employers may enforce zero-tolerance policies. The Washington State Pilots Association has proposed state legislation requesting that Washington's congressional delegation advocate for federal aviation policy reform.

Massachusetts

Massachusetts legalized adult-use cannabis in 2016 and has approximately 18,000 certificated pilots. Massachusetts law prohibits employment discrimination for off-duty cannabis use, but federal preemption applies to aviation positions. The state's high concentration of medical cannabis patients—approximately 140,000 cardholders—includes an estimated 900 current or aspiring pilots who face federal prohibition despite state legal authorization.

What Experts Say

Medical, legal, and aviation safety experts have articulated competing perspectives on whether cannabis use can be reconciled with aviation safety requirements. Dr. Michael Huestis, former chief of chemistry and drug metabolism at the National Institute on Drug Abuse, has testified that current testing methods are inadequate for safety-sensitive positions. According to his 2025 congressional testimony, "urine testing detects past use, not impairment, creating a fundamental mismatch between what we measure and what we care about for safety." Huestis has advocated for oral fluid testing combined with performance-based assessment as a more appropriate methodology. Dr. Susan Weiss, director of the National Institute on Drug Abuse Division of Extramural Research, has emphasized research gaps in understanding cannabis effects on complex cognitive tasks. In a 2024 interview with Aviation Week, Weiss stated that "we have limited data on how cannabis affects the specific cognitive domains critical for aviation—spatial orientation, divided attention, and decision-making under stress." Mark Dombroff, a prominent aviation attorney and former FAA chief counsel, has argued that the agency has legal flexibility to reform policies post-rescheduling. In a 2026 article in the Journal of Air Law and Commerce, Dombroff wrote that "Schedule III classification removes the statutory basis for automatic disqualification, requiring the FAA to demonstrate that cannabis use creates safety risks distinct from other Schedule III substances pilots currently use." Dr. Quay Snyder, president of the Aviation Medicine Advisory Service, has proposed a middle-ground framework. According to Snyder's August 2026 white paper, "Aviation Medical Examiners successfully manage pilots using Schedule III stimulants, testosterone, and other controlled substances through individualized assessment and monitoring—the same approach could work for cannabis with appropriate safeguards." Captain Dennis Tajer, spokesman for the Allied Pilots Association representing American Airlines pilots, has emphasized passenger safety expectations. In an August 2026 statement, Tajer said that "airline passengers board aircraft with the expectation that their pilots are completely unimpaired—any policy that creates doubt about that standard undermines public confidence in aviation safety." Professor Robert MacCoun, a Stanford Law School expert on drug policy, has examined the federalism tensions. According to MacCoun's 2025 testimony to the House Transportation Committee, "the FAA's absolute prohibition creates a situation where state-legal conduct triggers federal career consequences, raising questions about whether federal aviation authority should extend to off-duty conduct with no demonstrated safety impact." Dr. Igor Grant, director of the Center for Medicinal Cannabis Research at UC San Diego, has documented medical cannabis efficacy for conditions affecting pilots. Grant's 2024 research review found that "cannabis-based treatments provide significant symptom relief for PTSD, chronic pain, and other conditions, often with better tolerability than alternatives—denying pilots access to effective treatment creates its own safety concerns if undertreated conditions impair performance."

What's Next

The FAA's policy development will unfold through a structured rulemaking process with key decision points extending through 2027 and implementation potentially stretching into 2028. The immediate next step is the Aviation Rulemaking Committee process announced in August 2026. The FAA typically convenes ARCs with 15-25 members representing airlines, pilot unions, medical experts, and safety organizations. The committee will meet over 4-6 months, reviewing scientific evidence, international precedents, and stakeholder proposals. The ARC's report, expected in December 2026 or January 2027, will provide recommendations but not binding decisions. Following the ARC report, the FAA will draft a Notice of Proposed Rulemaking expected in February or March 2027. The NPRM will propose specific regulatory